H.Res. 161
Expressing the sense of the House of Representatives that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.
Referred to the Subcommittee on Health.
Sponsor
Rep. Rogers, Harold [R-KY-5]
Bill Details
- Update Date
- Nov 15, 2022
- Origin Chamber
- House
- Bill Type
- HRES
- Resolution Number
- 161
- Congress
- 113
- Introduced Date
- Apr 15, 2013
- Policy Area
- Health
- Is Law
- No
Referred to the Subcommittee on Health.
Source: House committee actions
Referred to the House Committee on Energy and Commerce.
Source: House floor actions
Introduced in House
Source: Library of Congress
Introduced in House
Source: Library of Congress
Expresses the sense of the House of Representatives that the Food and Drug Administration (FDA) should exercise its acknowledged authority to: (1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations, and (2) require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features.
Energy and Commerce Committee
Introduced in House
Apr 15, 2013